Dihydromyricetin

Dihydromyricetin (DHM), chemically ampelopsin, is a dihydroflavonol found at high concentration in the leaves and stems of the vine Ampelopsis grossedentata (vine tea) and in the fruit and seeds of the oriental raisin tree, Hovenia dulcis. Both plants have a long folk-medicine history in China, Korea and Japan as remedies for drunkenness, hangover and liver complaints, which is why DHM sits at the center of most modern anti-alcohol supplements. As a molecule it is a poorly water-soluble antioxidant flavonoid, and that low solubility drives one of its central practical problems: oral bioavailability is very low.

The most cited work on DHM concerns alcohol and the brain. In a widely referenced 2012 study, DHM counteracted acute alcohol intoxication in rats and blunted withdrawal signs including tolerance, anxiety and seizure susceptibility, while also reducing voluntary alcohol intake; mechanistically it acted at GABA-A receptors, antagonizing alcohol's potentiation of those receptors at the benzodiazepine site, and the effect was reversed when that site was blocked ^[1]. Follow-up pharmacology confirmed that DHM and its metabolites cross into the brain and correspond to the acute anti-intoxication effect in mice, though brain exposure is modest and short-lived ^[2]. This GABAergic activity is the basis for popular claims that DHM sobers you up or prevents hangovers, but it is important to note these mechanistic findings come from rodents at controlled doses.

DHM's second theme is the liver. Preclinical work shows it enhances the activity and expression of the alcohol-metabolizing enzymes alcohol dehydrogenase and aldehyde dehydrogenase, speeding ethanol and acetaldehyde clearance while shifting hepatic lipid metabolism toward less fat accumulation ^[3]. In non-alcoholic fatty liver disease (NAFLD), a small randomized double-blind trial in adults gave 300 mg twice daily for three months and reported lower ALT, AST, GGT, glucose, LDL cholesterol and insulin-resistance indices versus placebo, alongside reduced inflammatory markers ^[4]; this remains the strongest human dataset for DHM. Proposed mechanisms include AMPK activation, upregulation of the mitochondrial deacetylase SIRT3 to improve respiratory capacity and redox balance ^[5], and favorable shifts in gut microbiota and inflammatory signaling ^[6].

Beyond alcohol and liver, DHM has been explored preclinically for anxiety, neuroprotection and brain aging, largely through the same GABAergic and antioxidant pathways ^[7]. The honest summary is that DHM has a rich and fairly consistent preclinical record but a small and preliminary human record; its low oral bioavailability, short exposure and reliance on animal dosing mean the real-world magnitude of benefit in people, particularly for hangover prevention, is not well established.

DHM has a reassuring safety profile in the studies done so far; the 3-month human NAFLD trial at 600 mg/day reported no serious adverse events, and it has a long history of dietary use via Hovenia dulcis and vine tea. That said, human safety data are limited to small, short trials. Because DHM engages GABA-A receptors and can influence how alcohol acts, and because flavonoids like it can interact with drug-metabolizing enzymes (CYP450) and transporters, caution is warranted if you take medications that are sedating, that are metabolized by the liver, or that carry their own liver load. It is not a treatment for alcohol use disorder and should not be used as a reason to drink more or to drive after drinking. Pregnant or breastfeeding people and anyone with liver disease should talk to a clinician before use.